Hepatitis B - tenofovir disoproxil fumarate: review decision - October 2011 information
History
Documents created during the development process.
Background information
-
-
Appendix A: decision paper presented to the Institute's Guidance Executive
-
Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 106 KB)
-
Hepatitis B - tenofovir disoproxil fumarate: review proposal - July 2011 information
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 138 KB)
-
NICE guidance recommends tenofovir disoproxil for hepatitis B (PDF 67 KB)
Hepatitis B - tenofovir disoproxil fumarate: final appraisal determination
-
Hepatitis B - tenofovir disoproxil fumarate: final appraisal determination information
-
Hepatitis B - tenofovir disoproxil fumarate: final appraisal determination
-
Hepatitis B - tenofovir disoproxil fumarate: final appraisal determination (PDF 78 KB)
-
Response to consultee, commentator and public comments on the ACD and comments from website consultation
-
-
Response to consultee, commentator and public comments on the ACD and comments from website consultation from Evidence Review Group (Southampton Health Technology Assessment Centre)
-
-
Consultee and commentator comments on the ACD
-
Bristol Myers Squibb
-
-
Department of Health
-
-
Gilead
-
-
Gilead - comparisons
-
-
Hepatitis B Foundation UK
-
-
Roche
-
-
Royal College of Nursing
-
-
Royal College of Pathologists
-